Skip to main content

Table 1 Baseline characteristics for the modified intent-to-treat population (N = 14)

From: A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Age, mean ± SD, years

49.3 ± 8.7

Male sex, n (%)

14 (100)

Race, n (%)

  White

12 (85.7)

  Asian

2 (14.3)

  Body mass index (BMI), mean ± SD, kg/m2

33.9 ± 7.0

Smoking status, n (%)

  Never

4 (28.6)

  Current

5 (35.7)

  Former

5 (35.7)

Gout characteristics

  Time since first gout diagnosis, mean ± SD, years

13.8 ± 7.4

  Number of gout flares in the 12 months prior to Screening, mean ± SD

10.8 ± 8.5

  History of tophi, n (%)

13 (92.9)

  Baseline serum urate, mean ± SD, mg/dL

9.2 ± 2.5